Long-Acting C-Terminal Peptide–Modified hGH (MOD-4023): Results of a Safety and Dose-Finding Study in GHD Children

Nataliya Zelinska,1 Violeta Iotova,2 Julia Skorodok,3 Oleg Malievsky,4 Valentina Peterkova,5 Lubov Samsonova,6 Ron G. Rosenfeld,7 Zvi Zadik,8 Michal Jaron-Mendelson,9 Ronit Koren,9 Leanne Amitzi,9 Dmitri Raduk,10 Oren Hershkovitz,9 and Gili Hart9

1National Children’s Specialized Clinical Hospital, Kiev 04021, Ukraine; 2University Hospital ‘Sv. Marina’, Varna 9010, Bulgaria; 3St. Petersburg State Pediatric Medical Academy, St. Petersburg 194100, Russia; 4Bashkir State Medical University, Ufa 450000, Russia; 5Institute of Pediatric Endocrinology, Moscow 117036, Russia; 6Russian Medical Academy of Postgraduate Education, Moscow 123995, Russia; 7Oregon Health and Science University, Portland, Oregon 97239; 8Kaplan Medical Center, Rehovot 7661041, Israel; 9OPKO Biologics, Kiryat Gat 8211804, Israel; and 102nd Children City Clinic, Minsk 220017, Belarus

Context: Daily injections are required for growth hormone (GH) replacement therapy, which may cause low compliance as a result of inconvenience and distress in patients.

Objective: C-terminal peptide–modified human GH (MOD-4023) is developed for once-a-week dosing regimen in GH-deficient (GHD) adults and children. The present trial was a safety and dose-finding study for weekly MOD-4023 in GHD children.

Design: A multicenter, open-label, randomized, controlled phase 2 study in children with GHD, evaluating the safety, tolerability, pharmacokinetics/pharmacodynamics, and efficacy of three different weekly MOD-4023 doses, compared with daily recombinant human GH (r-hGH).

Setting: The trial was conducted in 14 endocrinology centers in Europe.

Patients: Fifty-three prepubertal children with GHD completed 12 months of treatment with either MOD-4023 (N = 42) or r-hGH (N = 11).

Interventions: C-terminal peptide–modified hGH (MOD-4023) was administered weekly at a dose of either 0.25, 0.48, or 0.66 mg/kg/wk and compared with daily hGH at a dose of 0.24 mg/kg/wk.

Results: MOD-4023 showed an estimated half-life approximately fivefold to 10-fold longer when compared with daily r-hGH. Insulin-like growth factor (IGF)-I and IGF-binding peptide 3 showed a dose-dependent increase during MOD-4023 treatment. IGF-I standard deviation score for MOD-4023 did not exceed +2. All MOD-4023 cohorts demonstrated adequate catch-up growth. The 0.66 mg/kg/wk dose demonstrated efficacy closest to daily r-hGH. No serious adverse events were observed during MOD-4023 treatment, and its tolerability was consistent with known properties of r-hGH.

Conclusions: This study confirms the long-acting properties of MOD-4023 and shows a promising safety and tolerability profile. This provides support for initiation of a phase 3 study in GHD children using a single weekly injection of MOD-4023. (J Clin Endocrinol Metab 102: 1578–1587, 2017)
Human growth hormone (hGH), a 191-amino acid pituitary protein, is an important endogenous factor responsible for skeletal growth and body mass. It stimulates the hepatic production and release of insulin-like growth factor (IGF)-I into the systemic circulation, and it is instrumental in the promotion of linear growth in children and in the control of metabolism and body composition in adults (1). Human GH deficiency (GHD) is the consequence of low or absent secretion of GH from the pituitary gland. In children, GHD results in inadequate circulating IGF-I levels and is manifested as abnormal linear growth (2). Children with complete absence of GH secretion are usually diagnosed before reaching the age of 3 years, whereas those with lesser degrees of deficiency are diagnosed at older ages.

Currently, daily GH supplementation is approved for the treatment of pediatric GHD. However, despite ongoing improvements in injection device design, daily subcutaneous injections remain inconvenient, painful, and distressing for many patients, leading to noncompliance, reduced efficacy, and increased health care costs. Compliance is a problem in up to 75% of teenagers and is associated with reduced growth velocity (3–5). A long-acting form of GH has the potential to reduce discomfort and inconvenience, and it can possibly provide substantial benefit by improving compliance and patients’ quality of life (6). Currently, several approaches are being investigated as means to prolong the circulatory half-life of hGH (7–11).

MOD-4023 [C-terminal peptide (CTP)-modified hGH] is a long-acting recombinant hGH (r-hGH) intended for use as long-term treatment of children with growth failure due to inadequate endogenous GH secretion, and as a replacement for endogenous GH in adults with GHD of either childhood or adult onset. This long-acting formulation is expected to obviate the need for the numerous injections required in standard treatment of GHD. This technology is based on CTP of the β-chain of human chorionic gonadotropin (12–14). As demonstrated in animal models (15), healthy subjects, and GHD adult patients (16), MOD-4023 may have the potential to be injected once per week, resulting in similar clinical efficacy to daily injections of r-hGH. The present trial investigated MOD-4023 in a phase 2 safety, tolerability, and dose-finding study in prepubertal pediatric patients with GHD. This was a randomized, active controlled study evaluating the safety, tolerability, and pharmacokinetics (PK)/pharmacodynamics (PD) profile of three different dosing regimens of weekly MOD-4023 compared with daily r-hGH (Genotropin).

Patients and Methods

Patients

The study was conducted at 14 sites in seven countries. Inclusion criteria included: (1) prepubertal children aged ≥3 years and not >10 years for girls or >11 years for boys, with either isolated GHD, or GHD as part of multiple pituitary hormone deficiency; (2) confirmed diagnosis of GHD by two different GH provocation tests defined as a peak plasma GH level of ≤10 ng/mL using a validated assay (insulin tolerance/arginine/clonidine/glucagon [with or without propranolol]/1-dopa plus propranolol); (3) bone age no older than chronological age, and should not be >9 years for girls and >10 years for boys; (4) no prior exposure to any rhGH therapy; (5) impaired height (Ht) and Ht velocity (HV) defined as Ht of at least 2.0 standard deviations (SD) below the mean Ht for chronological age and sex [HT SD score (SDS) ≤ −2.0] and annualized HV of <2.5th percentile for chronological age (HV < −0.7 SDS) and sex, according to the standard growth charts of Prader et al. (17); (6) body mass index (BMI) within ±2 SD of mean BMI for the chronological age and sex according to the 2000 Centers for Disease Control and Prevention standards (18); (7) baseline IGF-I level at least 1 SD below the mean IGF-I level standardized for age and sex (IGF-I SDS ≤ −1.0); (8) no signs/symptoms of intracranial hypertension; (9) children with multiple hormonal deficiencies must have been on stable replacement therapy for at least 3 months (or 6 months for thyroid replacement therapy) prior to the first study drug administration; (10) normal 46 XX karyotype for girls; and (11) written informed consent of the parent or legal guardian of the patient and assent of the patient. Exclusion criteria included: (1) past or present intracranial tumor growth; (2) history of radiation therapy or chemotherapy; (3) malnourished children, defined as serum albumin and iron below the lower limit of normal, and BMI < −2 SD for age and sex; (4) psychosocial dwarfism; (5) children born small for gestational age, that is, birth weight and/or birth length <2 SD for gestational age; (6) presence of anti-hGH antibodies at screening; (7) any clinically significant abnormality likely to affect growth or the ability to evaluate growth; (8) diabetes mellitus; (9) impaired fasting sugar (fasting blood sugar > 110 mg/dL or 6.1 mmol/L after repeated blood analysis); (10) chromosomal abnormalities and medical syndromes (Turner syndrome, Laron syndrome, Noonan syndrome, Prader–Willi syndrome, Russell–Silver syndrome, SHOX mutations/deletions, and skeletal dysplasias), with the exception of septo-optic dysplasia; (11) closed epiphyses; (12) concomitant administration of other treatments that may have an effect on growth such as anabolic steroids and methylphenidate, with the exception of hormone replacement therapies (thyroxin, hydrocortisone, desmopressin [DDAVP]); (13) children requiring glucocorticoid therapy (e.g., asthma) that are taking a dose of >400 μg/d of inhaled budesonide or equivalents for >1 month in a calendar year; (14) major medical conditions and/or presence of contraindication to r-hGH treatment; (15) known or suspected HIV-positive patient, or patient with advanced diseases such as AIDs or tuberculosis; (16) drug, substance, or alcohol abuse; (17) known hypersensitivity to the components of study medication; (18) other causes of short stature such as celiac disease, hypothyroidism, and rickets; (19) the patient and/or the parent/legal guardian are likely to be noncompliant in respect to study conduct; and (20) participation in any other trial of an investigational agent within 30 days prior to screening.

Study design

This was a phase 2 safety and dose-finding study of different MOD-4023 dose levels (0.25, 0.48, and 0.66 mg/kg/wk)
comparatively with daily r-hGH therapy (0.24 mg/mL/wk) in prepubertal GH-deficient children (ClinicalTrials.gov identifier NCT01592500). The patients were randomized in a 1:1:1:1 ratio to one of three different MOD-4023 weekly dose cohorts or the Genotropin daily cohort. The randomization scheme ensured that the study population consisted of up to 40 patients with peak GH levels of ≤7 ng/mL (up to 10 patients per cohort) and up to 16 patients with peak GH levels of >7 ng/mL and ≤10 ng/mL (up to four per cohort). The first 19 patients enrolled into the study were randomized via a Web-based system (Target Health, New York, NY) using the following conditions: (1) chronological age (3 to 7 years, >7 years); (2) Ht SDS minus target Ht SDS of ≤3 and >3. Owing to a programming error, this randomization resulted in an unexpected, unequal distribution of patients with regard to Ht SDS minus target Ht SDS and peak plasma GH level. For the remaining patients enrolled in the study, randomization was performed manually using the same dynamic minimization rule while considering the following stratification factors: (1) stimulation tests peak plasma GH level: patients with peak GH level ≥7 ng/mL and patients with peak GH level >7 ng/mL and ≤10 ng/mL; (2) patients with peak plasma GH level ≤7 ng/mL were additionally stratified by age (patients ≤7 years and patients >7 years). All dose levels tested were supported by a significant safety margin derived from the no observed adverse effect level established in nonclinical toxicology studies (15). The low dose administered to cohort 1 (0.25 mg MOD-4023 protein/kg/wk) is a weekly molar equivalent of the maximal approved dose for other pediatric indications (equivalent to 0.068 mg/kg/d). This study was carried out in compliance with the principles of good clinical practice. The study protocol was reviewed and approved by the ethics committees at each study site. The study included pubertal GH-deficient children (ClinicalTrials.gov identifier NCT01592500). The patients were randomized in a 1:1:1:1 ratio to one of three different MOD-4023 weekly dose cohorts (C1 to C3) or to the standard daily r-hGH control cohort (C4). The patients were introduced to their allocated MOD-4023 dose using a stepwise dose increase every 2 weeks. The active treatment period lasted for a total of 12 months.

IGF-I measurement

IGF-I was measured using the IDS-iSys chemiluminescence assay. Briefly, samples were incubated with an acidic solution to dissociate IGF-I from the binding proteins. This was followed by incubation with neutralization buffer, biotinylated anti–IGF-I monoclonal antibody, and acridinium-labeled anti–IGF-I monoclonal antibody. Streptavidin-labeled magnetic particles were added and an additional incubation step followed. The particles were captured, washed, and trigger reagents were added. The light emitted by the acridium label was directly proportional to the concentration of IGF-I in the original sample.

PK/PD analysis

PK/PD parameters were calculated using a population PK modeling approach, based on limited sampling in each patient. IGF-I SDS values were estimated using published reference tables (20). An empirical Bayesian estimation was performed to retrieve individual PK/PD model parameters. Individual concentration/time profiles were generated using rich sampling, and noncompartmental analysis was subsequently performed.
to estimate the area under the curve (AUC) and maximal concentration.

**Efficacy evaluation**

Height measurements were performed using a calibrated wall-mounted stadiometer. The arithmetic mean of three independent readings was obtained at each visit. Average Ht, SD of Ht, HV, and HV SDS were derived from the standards of Prader et al. (17).

**Safety evaluations**

Safety evaluations included vital signs, injection-site reactions, immunogenic response, and laboratory safety assessments. The latter included routine hematology and serum biochemistry, glucose and lipid parameters, as well as hormonal (thyroid and adrenal) status evaluation. For antibody assessments, qualitative validated methods were used to detect whether binding and/or neutralizing antibodies developed following once-weekly administration of MOD-4023 compared with daily r-hGH treatment. Serum samples for immunogenicity analysis were collected at predose and after 6 and 12 months of MOD-4023/hGH treatment using the anti-drug antibodies (ADAs) and neutralizing Ab methods for detection. Each sample was analyzed in screen format. Samples reactive for anti–MOD-4023 antibodies were confirmed for MOD-4023 specificity. Samples confirmed positive for anti–MOD-4023-binding antibodies were titrated and analyzed for hGH and CTP specificity, as well as for anti–MOD-4023 and anti-hGH neutralizing activity using a cell-based assay. The assay is based on the ability of hGH/MOD-4023 to induce cell proliferation by binding to the human GH receptor expressed on the surface of human BaF2B2 cells. The presence of anti–MOD-4023 neutralizing antibodies was determined qualitatively by measuring the inhibition of the GH proliferative effect. A titration curve of anti–MOD-4023 in 2% normal pooled human serum at specific concentrations and tested samples was preincubated with a fixed concentration of MOD-4023 (25 ng/mL) at room temperature. The cells were subsequently added and incubated for 18 ± 2 hours at 37°C and 5% CO2. Following the incubation period, 30 μL of CellTiter96 AQueous One solution (Promega, Madison, WI) was added and incubated. The optical density at 490 nm is proportional to the number of living cells and inversely proportional to the amount of neutralizing antibodies.

**Results**

**Patient disposition and characteristics**

A total of 54 prepubertal children with either isolated GHD or GHD as a part of multiple pituitary hormone deficiency were enrolled in the study. One patient was enrolled into the study but discontinued prior to receiving any treatment; 53 children completed 12 months of treatment with either MOD-4023 (N = 42) or r-hGH (Genotropin; N = 11). One patient was enrolled but misdiagnosed as GHD and therefore was excluded from the per-protocol efficacy analysis but was included in the safety and PK and PD analyses. Despite the limited sample size in each cohort, the baseline characteristics of the patients completing 12 months of treatment were well balanced among the four cohorts (Table 1).

**Pharmacokinetics**

To evaluate the PK/PD profile of MOD-4023, a population-based PK/PD analysis was conducted. Additionally, a naive-pooled approach was used to estimate mean PK parameters [Table 2; Fig. 2(a) and 2(b)]. MOD-4023 showed an estimated half-life approximately fivefold to 10-fold longer when compared with daily r-hGH. Time of maximal concentration was estimated to be at 12 hours for MOD-4023, as opposed to 2 hours for the daily Genotropin comparator arm, reaching trough levels by 168 hours. The MOD-4023 AUC increased in a proportional manner to the dose. The serum level of MOD-4023 administered weekly reached steady-state levels after 7 to 10 weeks, without an increase in plasma levels (data not shown).

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Cohort 1: 0.25 mg/kg/wk (N = 13)</th>
<th>Cohort 2: 0.48 mg/kg/wk (N = 15)</th>
<th>Cohort 3: 0.66 mg/kg/wk (N = 14)</th>
<th>Cohort 4: Genotropin (N = 11)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean age, y</td>
<td>6.2 ± 2.2</td>
<td>5.8 ± 2.3</td>
<td>6.1 ± 2.2</td>
<td>5.7 ± 1.9</td>
</tr>
<tr>
<td>Minimum, maximum age, y</td>
<td>(4, 11)</td>
<td>(3, 10)</td>
<td>(3, 10)</td>
<td>(4, 9)</td>
</tr>
<tr>
<td>Male</td>
<td>10 (76.9%)</td>
<td>9 (60.0%)</td>
<td>9 (64.3%)</td>
<td>8 (72.7%)</td>
</tr>
<tr>
<td>Female</td>
<td>3 (23.1%)</td>
<td>6 (40.0%)</td>
<td>5 (35.7%)</td>
<td>3 (27.3%)</td>
</tr>
<tr>
<td>White</td>
<td>12 (92.3%)</td>
<td>14 (93.3%)</td>
<td>14 (100.0%)</td>
<td>10 (90.9%)</td>
</tr>
<tr>
<td>Total non-white</td>
<td>1 (7.7%)</td>
<td>0 (0%)</td>
<td>0 (0%)</td>
<td>1 (9.1%)</td>
</tr>
<tr>
<td>Patients with IGHD</td>
<td>8 (61.5%)</td>
<td>11 (73.3%)</td>
<td>11 (78.5%)</td>
<td>9 (81.8%)</td>
</tr>
<tr>
<td>Patients with MPHD</td>
<td>5 (38.5%)</td>
<td>4 (26.7%)</td>
<td>3 (21.5%)</td>
<td>2 (18.2%)</td>
</tr>
<tr>
<td>Ht SDS</td>
<td>−3.64 ± 0.97</td>
<td>−3.72 ± 0.87</td>
<td>−4.21 ± 1.45</td>
<td>−4.22 ± 1.58</td>
</tr>
<tr>
<td>Ht SDS – THSDS</td>
<td>−3.22 ± 0.95</td>
<td>−3.00 ± 0.70</td>
<td>−3.36 ± 1.54</td>
<td>−3.68 ± 1.70</td>
</tr>
<tr>
<td>HV SDS</td>
<td>−2.93 ± 1.42</td>
<td>−2.68 ± 1.00</td>
<td>−3.01 ± 1.42</td>
<td>−3.29 ± 1.91</td>
</tr>
<tr>
<td>Peak GH, ng/mL</td>
<td>3.93 ± 3.15</td>
<td>4.13 ± 2.64</td>
<td>3.97 ± 2.97</td>
<td>3.82 ± 2.78</td>
</tr>
<tr>
<td>IGF-1, ng/mL</td>
<td>−2.21 ± 0.84</td>
<td>−2.13 ± 0.77</td>
<td>−1.97 ± 0.83</td>
<td>−2.15 ± 0.94</td>
</tr>
</tbody>
</table>

Abbreviations: IGHD, isolated GHD; MPHD, GHD associated with multiple deficiencies; THSDS, target height SDS.
**Pharmacodynamics**

In terms of weekly trend, IGF-I was found to increase in a dose-dependent manner during treatment with MOD-4023 [calculated as change from baseline values and shown in Fig. 2(c)]. Additionally, the calculated IGF-I SDS values for the MOD-4023 cohorts were shown to be within the normal range without exceeding +2 SDS (with the exception of one patient from the 0.66 mg/kg/wk cohort who showed a transient slight increase of IGF-I SDS for most of the study period, based on sampling of patients at 48 to 72 hours after MOD-4023 dosing [Fig. 2(d)]. The IGF-I SDS profile for cohort 1 (0.25 mg/kg/wk) decreased during the second half of the week, and reached a mean value of approximately −2 SDS.

IGF-I SDS levels continued to increase gradually in a dose-dependent manner during the 12 months of the study without reaching excessive IGF-I values for all but one patient (transiently) [Fig. 2(e) and 2(f)]. For most of the analysis period, based on sampling of patients at 48 to 72 hours after MOD-4023 dosing [Fig. 2(d)]. The IGF-I SDS profile for cohort 1 (0.25 mg/kg/wk) decreased during the second half of the week, and reached a mean value of approximately −2 SDS.

IGF-I SDS levels continued to increase gradually in a dose-dependent manner during the 12 months of the study without reaching excessive IGF-I values for all but one patient (transiently) [Fig. 2(e) and 2(f)]. For most of the analysis period, based on sampling of patients at 48 to 72 hours after MOD-4023 dosing [Fig. 2(d)]. The IGF-I SDS profile for cohort 1 (0.25 mg/kg/wk) decreased during the second half of the week, and reached a mean value of approximately −2 SDS.

IGF-I SDS levels continued to increase gradually in a dose-dependent manner during the 12 months of the study without reaching excessive IGF-I values for all but one patient (transiently) [Fig. 2(e) and 2(f)]. For most of the analysis period, based on sampling of patients at 48 to 72 hours after MOD-4023 dosing [Fig. 2(d)]. The IGF-I SDS profile for cohort 1 (0.25 mg/kg/wk) decreased during the second half of the week, and reached a mean value of approximately −2 SDS.

**Efficacy evaluation**

The annualized efficacy data for the four treatment groups are presented in Fig. 3 for patients completing 12 months of treatment (n = 52). The mean HV in the three MOD-4023 randomized dose groups and the daily GH group are presented in Fig. 3(a). During the first 12 months of treatment, catch-up growth (compared with the normal population) occurred in all four groups. Among the three dose cohorts of patients treated with MOD-4023, the mean growth rate was lowest in the 0.25 mg/kg/wk MOD-4023 dose group (10.4 cm/y) and highest in the 0.66 mg/kg/wk MOD-4023 dose group (11.93 cm/y). The two dose groups of 0.25 and 0.48 mg/kg/wk MOD-4023 demonstrated reduced mean annualized HV [10.4 ± 2.6 [range, 6.2 to 14.4] and 11.0 ± 2.3 [range, 6.5 to 14.5] cm/y, respectively] compared with daily Genotropin (12.5 ± 2.1 cm/y; range, 9.2 to 16.0 cm/y), whereas the 0.66 mg/kg/wk dose group showed a more pronounced response (11.9 ± 3.5 cm/y; range, 6.4 to 18.3 cm/y), comparable to that of the daily hGH. The mean HV SDS and mean ΔHt SDS following 12 months of treatment are presented in Fig. 3(b) and 3(c). Most patients transitioned from a negative HV SDS (below the age-adjusted mean, and in several cases, severely below the mean) to a substantially positive SDS (above 0, and above the upper age-adjusted normal range). The differences in age-adjusted Ht SDS following 12 months of treatment are presented in Fig. 3(c). Most of the patients in the study demonstrated an improvement in Ht SDS compared with pretreatment values following 12 months of treatment. The mean gain in MOD-4023 dose groups after 12 months of treatment ranged from 1.14 to 1.45 SDS. Only the high dose of MOD-4023 (0.66 mg/kg/wk) demonstrated a gain in Ht SDS comparable to the active control group (1.45 vs 1.54, respectively).

**Safety**

A summary of the adverse events (AEs) is provided in Table 3. Overall, 37 of 53 patients (69.8%) experienced a total of 145 AEs during the study. Eight patients (72.7%) reported a total of 33 AEs during the reporting period with daily r-hGH, and there were no severe AEs and no serious AEs (SAEs) during treatment with daily r-hGH for up to 12 months. Twenty-nine patients (69.0%) reported

<table>
<thead>
<tr>
<th>Table 2. Mean PK Parameters for MOD-4023 and r-hGH</th>
</tr>
</thead>
<tbody>
<tr>
<td>Weekly MOD-4023</td>
</tr>
<tr>
<td>Parameter</td>
</tr>
<tr>
<td>$t_{1/2}$, h</td>
</tr>
<tr>
<td>$t_{max}$, h</td>
</tr>
<tr>
<td>AUClow, ng/mL-h</td>
</tr>
<tr>
<td>$C_{max}$, ng/mL</td>
</tr>
</tbody>
</table>

Abbreviations: $C_{max}$, maximal concentration; $t_{1/2}$, half-life; $t_{max}$, time of maximal concentration.

1582 Zelinska et al MOD-4023 Phase 2 Study in GHD Children J Clin Endocrinol Metab, May 2017, 102(5):1578–1587
Figure 2. PK and PD profiles of MOD-4023 administered weekly. The weekly plasma concentration/time profiles for (a) weekly MOD-4023 and (b) daily r-hGH are presented. MOD-4023 serum levels were measured at the final randomized dose (following the second dose). r-hGH serum concentration was measured following 2 weeks of daily administration. At each time point, the mean values represent an average of three to four patients. Weekly trends of IGF-I levels are shown as mean change from (c) baseline and (d) mean SDS. (e) IGF-I serum levels and (f) IGF-I SDS trends for patients completing 12 months of treatment.
112 AEs during treatment with MOD-4023, with no severe AEs and no SAEs. Of the reported AEs, none led to MOD-4023 or daily r-hGH treatment withdrawal. Nine patients (21.4%) reported AEs in cohort 1, whereas 10 patients (23.8%) reported AEs in both cohorts 2 and 3. Most patients reported little injection site pain (score of 2 to 3 out of 5), with the exception of one patient (0.66 mg/kg/wk MOD-4023 dose group) who experienced severe pain for 4 days.

No significant findings attributed to MOD-4023 were observed in glucose metabolism (glucose, hemoglobin A1c, and insulin); the single case of impaired fasting glucose (0.25 mg/kg/wk cohort) was mild and clinically insignificant. No adverse effects attributed to MOD-4023 were observed in thyrotropin, free triiodothyronine, free thyroxine, and cortisol levels. Most mean blood chemistry values were within normal limits, with the exception of relative eosinophil and relative lymphocyte levels, which were also high at screening. The immunogenicity data showed low titers of nonneutralizing anti-MOD-4023 antibodies. Overall ADA incidence was similar for the study drug and the control group. For MOD-4023 the incidence rate was 11.9% (5/42; three patients in the 0.48 mg/kg/wk cohort [20.0%] and two in the 0.66 mg/kg/wk cohort [14.3%]), and 9.1% (1/11) for Genotropin. No anti-CTP antibodies were

Table 3. Summary of Adverse Events Possibly, Probably, or Definitely Related to MOD-4023 Treatment

<table>
<thead>
<tr>
<th></th>
<th>MOD-4023 Treatment</th>
<th>r-hGH Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Cohort 1</td>
<td>Cohort 2</td>
</tr>
<tr>
<td>No. of patients</td>
<td>13</td>
<td>15</td>
</tr>
<tr>
<td>No. of patients with any AEs</td>
<td>9</td>
<td>10</td>
</tr>
<tr>
<td>No. of AEs possibly, probably or definitely related to MOD-4023 treatment</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>Anemia</td>
<td>0</td>
<td>2</td>
</tr>
<tr>
<td>Adrenal insufficiency</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>Secondary adrenocortical insufficiency</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>Erythema</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Swelling</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Hematoma</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Impaired fasting glucose</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>Hematuria</td>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>
observed. No antibody-related AEs were reported during the study.

**Discussion**

This study presents 12-month efficacy, safety, and tolerability results of OPKO Biologics’ phase 2 clinical trial in prepubertal children with GHD. This study is the most recent stage in the clinical development of MOD-4023, a long-acting hGH utilizing OPKO Biologics’ unique and versatile CTP technology. Fusing the protein to CTP enables the elongation of the protein’s half-life using a naturally occurring human peptide that also significantly reduces the risk of an adverse immune response compared with other long-acting preparations currently in development. MOD-4023 was shown previously to have a favorable safety and tolerability profile in both a phase 1 study in healthy adults and in a once-weekly dosing regimen in a phase 2 trial in GHD adults (16). The present study showed that the estimated half-life of MOD-4023 administered weekly was longer than that of daily r-hGH. The latter’s PK profile and half-life are in line with daily r-hGH profiles reported in the literature (21). The variability observed in respect to MOD-4023 exposure is predominantly related to intrapatient variability and the small number of patients per cohort.

IGF-I, a validated surrogate marker for hGH activity (20, 22), increased in response to treatment with MOD-4023 [in line with the anticipated response for daily GH, as reported in the past by Peter et al. (21)]. IGF-I SDS values did not exceed the normal range for most of the study, except transiently in rare situations. The rapid drop in IGF-I SDS values for cohort 1 (0.25 mg/kg/wk) during the second part of the week to a suboptimal mean value suggests that this dose might not provide an optimal weekly IGF-I profile during long-term MOD-4023 therapy. In general, IGF-I SDS values showed an upward trend throughout the study. The daily r-hGH comparator Genotropin also demonstrated an elevation in IGF-I SDS values, in line with previous reports in the literature (23, 24), and showed a similar trend to that observed in the two highest dose cohorts of MOD-4023. This comparable outcome can be explained by the fairly small increase (~30%) in the MOD-4023 dose between the 0.48 and 0.66 mg/kg/wk cohorts, as opposed to a larger increment of almost 50% in the MOD-4023 dose in the 0.25 mg/kg/wk cohort as compared with the 0.48 mg/kg/wk cohort. A significant effect on IGF-I might be less pronounced as the increment in MOD-4023 is reduced, in line with Cohen et al. (24), who demonstrated a modest increase in IGF-I when increasing the dose by 100%.

MOD-4023 trough levels measured on the 23rd week of treatment further confirmed that residual MOD-4023 levels at all three doses were very low to undetectable (data not shown).

As shown in previous preclinical studies, the specific activity of MOD-4023 is lower than that of r-hGH (15). This indicates that comparison of the biological/physiological effect of weekly MOD-4023 and daily r-hGH is more appropriate than a direct molar comparison. In terms of efficacy, all cohorts demonstrated adequate catch-up growth after 12 months of MOD-4023 treatment in comparison with the normal age-adjusted population. All patients responded very well to treatment, as reflected by the 12-month increase in HV SDS and ΔHt SDS values, and in most cases, the growth rate was accelerated relative to the normal age group. The 0.66 mg/kg/wk dose demonstrated the best annualized HV, HV SDS, and ΔHt SDS values, with values that were the closest to the daily r-hGH results. With respect to correlation between the IGF-I SDS profile and annual HV, although IGF-I increases with GH treatment, there is no direct or validated correlation between the IGF-I and annual HV (24). This suggest that although the level of IGF-I impacts growth, other parameters are affected by baseline characteristics, including genetic background (25, 26). Finally, it is well known that GH might also have a direct impact on growth response, independently of IGF-I (27).

MOD-4023 was shown to be safe during treatment of up to 12 months, with no SAEs, and tolerability consistent with known properties of r-hGH products. No patients withdrew from the study due to an AE associated with the investigational product, indicating that MOD-4023 was well tolerated by all patients. There was no discernible trend of AE frequency with escalating doses of MOD-4023. Relatively few AEs were attributed to MOD-4023 overall, and those that were attributed to MOD-4023 are of a similar nature and severity as those encountered with daily r-hGH products. One case of mild adrenal insufficiency and one case of moderate secondary adrenocortical insufficiency were assessed as being possibly related to study drug administration, because GH treatment may unmask previously undiagnosed or subclinical hypoadrenalism (28). During the first 12 months of the phase 2 study in the GHD pediatric population, in line with previous phase 2 data in GHD adults, MOD-4023 demonstrated a promising immunogenic profile, with no detection of binding antibodies against the CTP moiety or any neutralizing activity. Subjects that had developed antibodies against MOD-4023 demonstrated adequate annual HV and HV SDS ranges (data not shown), suggesting that the presence of ADAs had no effect on MOD-4023 efficacy.

In conclusion, the present study confirms the long-acting properties of MOD-4023 and shows a promising
12-month safety and tolerability profile for this novel compound. Taken together, these provide support for the initiation of a phase 3 study in GHD children using a single weekly injection of MOD-4023. Based on the 12-month data presented in the present study, it is most likely that a MOD-4023 dose of 0.66 mg/kg/wk will provide an annualized HV comparable to daily rhGH at a dose of 34 μg/kg/d. These doses will therefore serve as a basis for the upcoming phase 3 study.

Acknowledgments

The authors thank Dr. Doron Calo (OPKO Biologics) for assistance in technical editing of the manuscript.

Address all correspondence and requests for reprints to: Gili Hart, PhD, OPKO Biologics, 16 Ashlagan Street, Kiryat Gat, Israel. E-mail: ghart@opko.com

Clinical trial registry: ClinicalTrials.gov no. NCT01592500 (registered 2 May 2012).


